^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Tempus xF+ Panel

Company:
Tempus
Type:
Laboratory Developed Test
Related tests:
Evidence

News

23d
Leveraging a comprehensive genomic data library for detecting clonal hematopoiesis in liquid biopsy (AACR 2024)
A novel classifier trained on multiple orthogonal bioinformatics features can reliably distinguish CH from tumor-derived variants using only liquid biopsy data with high accuracy, including high sensitivity and high specificity.
Genomic data • Liquid biopsy • Biopsy
|
TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
|
Tempus xT Assay • Tempus xF+ Panel
1year
Tempus announces new multi-omics collaboration with Actuate Therapeutics (Tempus Press Release)
"Tempus...announced a brand-new multi-omics collaboration with Actuate Therapeutics, Inc...to support its ongoing Phase 1/2 Study of elraglusib, formerly known as 9-ING-41 (NCT03678883). The Tempus’ xF+ liquid biopsy and Research Use Only (RUO) DNA methylation tests will be used to help discover and further validate biomarker profiles in patients who may benefit from treatment with elraglusib, a selective GSK-3β inhibitor."
Licensing / partnership
|
Tempus xF+ Panel
|
elraglusib (9-ING-41)
almost2years
Tempus to launch largest clinically available liquid biopsy panel, xF+ (Businesswire)
"Tempus...announced the expansion of its comprehensive genomic profiling offerings with xF+, a new non-invasive, liquid biopsy panel of 523 genes, focused on pathogenic mutations in cell-free DNA (cfDNA). The test will originally be available on a limited basis alongside xF, Tempus’ 105-gene liquid biopsy assay, with a broader launch slated for later this year."
Launch
|
Tempus xF+ Panel
almost2years
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. (ASCO 2022)
"In the largest study of its kind, we show that dual tumor tissue and ctDNA testing—with samples collected either concurrently or longitudinally—identified more patients with actionable alterations than single modality testing alone and therefore should be considered as part of routine NGS testing. Additional studies to explore the genetic and intra-patient tumor heterogeneity of these variants as well as the impact of time between tissue and plasma sampling assessments and implications for timing of therapeutic recommendations are underway."
Clinical
|
Tempus xT Assay • Tempus xF Assay • Tempus xF+ Panel
almost2years
Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116). (ASCO 2022)
ctDNA testing is a reliable method to detect DNA damage repair LOF alterations but is limited to alterations and genes/exons covered by the ctDNA test. CH alterations are frequent, especially for ATM, thus matched normal analysis is preferred. Changes in ctDNA as early as 3 wks were associated with improved outcomes and may be useful for evaluating drug activity in heterogenous tumors outside of traditional efficacy endpoints.
P1/2 data • Clinical • PARP Biomarker • BRCA Biomarker • Circulating tumor DNA
|
KRAS (KRAS proto-oncogene GTPase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • MUC16 (Mucin 16, Cell Surface Associated) • ATR (Ataxia telangiectasia and Rad3-related protein) • RAD51C (RAD51 paralog C)
|
KRAS mutation • BRCA1 mutation • PALB2 mutation
|
Guardant360® CDx • Tempus xF Assay • Tempus xF+ Panel
|
camonsertib (RP-3500)
almost2years
Molecular profiles of gastric adenocarcinoma among Hispanic patients at a safety-net healthcare system. (ASCO 2022)
CDH1 mutations, which are associated with familial gastric cancers and more aggressive disease, were present in 33% of Hispanic patients with gastric adenocarcinoma in our study. Nearly half of these identified patients were younger than 50 years old. The high frequency of CDH1 mutations may contribute to the unique pathogenesis of gastric cancers in Hispanic patients.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • LRP1B (LDL Receptor Related Protein 1B) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • RHOA (Ras homolog family member A)
|
TP53 mutation • CDH1 mutation
|
Tempus xT Assay • Tempus xF Assay • Tempus xF+ Panel